Mink Therapeutics Stock Analysis

Mink Stock Analysis Notes

About 75.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.59. Mink Therapeutics had not issued any dividends in recent years. MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc. Mink Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 33 people. To learn more about Mink Therapeutics call Jennifer Buell at 212 994 8250 or check out https://minktherapeutics.com.

Mink Therapeutics Investment Alerts

Mink Therapeutics Upcoming and Recent Events

Mink Largest EPS Surprises

View All Earnings Estimates

Mink Stock Institutional Investors

Note, although Mink Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Mink Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 37.48 M.

Mink Profitablity

Management Efficiency

Mink Therapeutics has return on total asset (ROA) of (1.1124) % which means that it has lost $1.1124 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.3898) %, meaning that it created substantial loss on money invested by shareholders. Mink Therapeutics' management efficiency ratios could be used to measure how well Mink Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 3.51 in 2024, whereas Return On Tangible Assets are likely to drop (5.18) in 2024. At this time, Mink Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 15.7 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 4.3 M in 2024.

Technical Drivers

As of the 12th of June 2024, Mink Therapeutics secures the Mean Deviation of 3.9, downside deviation of 6.0, and Risk Adjusted Performance of 0.0338. Mink Therapeutics technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices.

Mink Therapeutics Price Movement Analysis

Mink Therapeutics Insider Trading Activities

Mink Therapeutics Predictive Daily Indicators

Mink Therapeutics Forecast Models

Mink Therapeutics' time-series forecasting models are one of many Mink Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Mink Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Mink Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Mink shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Mink Therapeutics. By using and applying Mink Stock analysis, traders can create a robust methodology for identifying Mink entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Mink analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Mink analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Mink Therapeutics stock analysis indicators help investors evaluate how Mink Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Mink Therapeutics shares will generate the highest return on investment. By understating and applying Mink Therapeutics stock analysis, traders can identify Mink Therapeutics position entry and exit signals to maximize returns.

When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.